VERTEX PHARMACEUTICALS INC / MA (VRTX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 4.41B USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $4.41B | (m) |
| 2026-03-31 | (m) | $4.34B | (m) |
| 2025-12-31 | (m) | $3.95B | (m) |
| 2025-09-30 | (m) | $3.68B | (m) |
| 2025-06-30 | (m) | $3.64B | (m) |
| 2025-03-31 | (m) | $-988.90M | (m) |
| 2024-12-31 | (m) | $-535.60M | (m) |
| 2024-09-30 | (m) | $-479.80M | (m) |
| 2024-06-30 | (m) | $-489.90M | (m) |
| 2024-03-31 | (m) | $4.02B | (m) |
| 2023-12-31 | (m) | $3.62B | (m) |
| 2023-09-30 | (m) | $3.47B | (m) |
| 2023-06-30 | (m) | $3.36B | (m) |
| 2023-03-31 | (m) | $3.26B | (m) |
| 2022-12-31 | (m) | $3.32B | (m) |
| 2022-09-30 | (m) | $3.27B | (m) |
| 2022-06-30 | (m) | $3.19B | (m) |
| 2022-03-31 | (m) | $2.45B | (m) |
| 2021-12-31 | (m) | $2.34B | (m) |
| 2021-09-30 | (m) | $2.18B | (m) |
| 2021-06-30 | (m) | $1.99B | (m) |
| 2021-03-31 | (m) | $2.76B | (m) |
| 2020-12-31 | (m) | $2.71B | (m) |
| 2020-09-30 | (m) | $2.69B | (m) |
| 2020-06-30 | (m) | $2.08B | (m) |
| 2020-03-31 | (m) | $1.51B | (m) |
| 2019-12-31 | (m) | $1.18B | (m) |
| 2019-09-30 | (m) | $2.14B | (m) |
| 2019-06-30 | (m) | $2.22B | (m) |
| 2019-03-31 | (m) | $2.16B | (m) |
| 2018-12-31 | (m) | $2.10B | (m) |
| 2018-09-30 | (m) | $647.05M | (m) |
| 2018-06-30 | (m) | $415.36M | (m) |
| 2018-03-31 | (m) | $225.99M | (m) |
| 2017-12-31 | (m) | $263.48M | (m) |
| 2017-09-30 | (m) | $195.75M | (m) |
| 2017-06-30 | (m) | $259.86M | (m) |
| 2017-03-31 | (m) | $177.34M | (m) |
| 2016-12-31 | (m) | $-112.05M | (m) |
| 2016-09-30 | (m) | $-218.73M | (m) |
| 2016-06-30 | (m) | $-275.04M | (m) |
| 2016-03-31 | (m) | $-399.36M | (m) |
| 2015-12-31 | (m) | $-556.33M | (m) |
| 2015-09-30 | (m) | $-659.26M | (m) |
| 2015-06-30 | (m) | $-734.17M | (m) |
| 2015-03-31 | (m) | $-704.70M | (m) |
| 2014-12-31 | (m) | $-738.55M | (m) |
| 2014-09-30 | (m) | $-517.61M | (m) |
| 2014-06-30 | (m) | $-471.69M | (m) |
| 2014-03-31 | (m) | $-369.47M | (m) |
| 2013-12-31 | (m) | $-445.03M | (m) |
| 2013-09-30 | (m) | $-565.46M | (m) |
| 2013-06-30 | (m) | $-498.87M | (m) |
| 2013-03-31 | (m) | $-506.64M | (m) |
| 2012-12-31 | (m) | $-107.03M | (m) |
| 2012-09-30 | (m) | $127.75M | (m) |
| 2012-06-30 | (m) | $406.40M | (m) |
| 2012-03-31 | (m) | $297.26M | (m) |
| 2011-12-31 | (m) | $29.57M | (m) |
| 2011-09-30 | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) |
| 2011-03-31 | (m) | $-765.45M | (m) |
| 2010-12-31 | (m) | $-754.63M | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) |
| 2009-12-31 | (m) | $-642.18M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |